Fusion Antibodies plc (LON:FAB – Get Free Report) shares dropped 1.2% on Friday . The company traded as low as GBX 4.20 ($0.05) and last traded at GBX 4.25 ($0.05). Approximately 116,900 shares were ...
Incyte (Nasdaq: INCY) today announced that the Company will present new data from across its oncology portfolio at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego. “These ...
There are approx. 25+ key companies which are developing the therapies for Cutaneous T-cell lymphoma. The companies which have their Cutaneous T-cell lymphoma drug candidates in the most advanced ...
In October 2024, Topas Therapeutics announced positive topline results from its Phase IIa trial of TPM502, in patients with celiac disease. The study data serves as the first clinical proof of concept ...
Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases ...
Fusion Antibodies PLC is engaged in the research, development and manufacturing of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...
The antibody fusion protein IBI363, which combines IL2 and an anti–PD-1 antibody, showed strong efficacy in immunotherapy-naive patients with advanced melanoma, including in immunologically “cold” ...
Pacific Fusion is building a fast pulser, similar to Sandia’s well-proven Z Machine. Pacific Fusion A California-based firm is reportedly following a unique approach to achieve fusion energy.